按业绩预告中位值测算，2025年第四季度，公司营业收入同比增长 14.79%、归属于上市公司股东的扣 除非经常性损益后的净利润同比增长 54.09%、经调整的非《国际财务报告准则》下归属于上市公司股 东的净利润同比增长16.36%。 智通财经APP讯，康龙化成(03759)公布，该集团预期2025年实现营收约138.72亿-142.4亿元，同比增长 13%-16%;归属于上市公司股东的净利润约16.14亿-16.86亿元，同比下降6%-10%;扣非净利约15.07 亿-15.62亿元，同比增长36%-41%;经调整的非《国际财务报告准则》下归属于上市公司股东的净利润约 17.675亿-18.48亿元，同比增长10%-15%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （股份代號：3759） 內幕消息公告 有關2025年年度業績預告 本公告乃由康龍化成（北京）新藥技術股份有限公司（「本公司」，連同其附屬公司 「本集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及 證券及期貨條例（香港法例第571章）第XIVA部項下的內幕消息條文（定義見上市 規則）而作出。 以下為本公司的2025年年度業績預告。本業績預告所載之財務數據未經審計，除 經調整的非《國際財務報告準則》下歸屬於上市公司股東的淨利潤或另有註釋外， 本業績預告所載之財務數據根據中國企業會計準則編製。 一. 2025年年度業績預告情況 預計營業收入、歸屬於上市公司股東的扣除非經常性損益後的淨利潤以 及經調整的非《國際財務報告準則》下歸屬於上市公司股東的淨利潤同向 上升 ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

康龙化成表示，在主营业务持续向好的情形下，主要由于非经常性损益的下降，公司归属净利润相比上 年同期下降6%-10%。上年同期主要由于处置PROTEOLOGIX, INC.股权影响，归属于上市公司股东的非 经常性损益为68543.7万元。 北京商报讯（记者 丁宁）1月13日晚间，康龙化成（300759）发布2025年度业绩预告显示，公司预计 2025年实现归属净利润16.14亿元至16.86亿元，比上年同期下降6%–10%。 ...

格隆汇1月13日丨康龙化成(300759.SZ)公布，预计2025年营业收入1,387,162.56万元–1,423,989.89万元， 比上年同期增长13%–16%，归属于上市公司股东的净利润161,401.57万元–168,574.98万元，比上年同期 下降6%–10%，归属于上市公司股东的扣除非经常性损益后的净利润150,676.29万元–156,215.86万元， 比上年同期增长36%–41%。 公司坚定地推行"全流程、一体化、国际化、多疗法"的核心战略，以客户需求为导向，深化全球化布 局，强化技术平台建设。2025年，公司预计营业收入同比增长13%-16%、归属于上市公司股东的扣除非 经常性损益后的净利润同比增长36%-41%、经调整的非《国际财务报告准则》下归属于上市公司股东的 净利润同比增长10%-15%。按业绩预告中位值测算，2025年第四季度，公司营业收入同比增长 14.79%、归属于上市公司股东的扣除非经常性损益后的净利润同比增长54.09%、经调整的非《国际财 务报告准则》下归属于上市公司股东的净利润同比增长16.36%。 如上所述，报告期内归属于上市公司股东的非经常性损益为人民币11, ...

智通财经APP讯，康龙化成(300759.SZ)发布2025年年度业绩预告，预计2025年度归属于上市公司股东的 净利润16.14亿元至16.86亿元，同比下降6%–10%。 经公司初步测算，2025年度归属于上市公司股东的非经常性损益约为人民币11,000 万元至人民币13,000 万元，主要包括计入当期损益的政府补助、其他非流动金融资产公允价值变动收益及投资的中低风险银 行理财产品相关损益等。 ...

21智讯1月13日电，康龙化成发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 161401.57万元—168574.98万元，同比预减6.00%—10.00%；预计2025年全年归属于上市公司股东的扣 除非经常性损益的净利润为150676.29万元—156215.86万元，同比预增36.00%—41.00%，变动原因为： 公司坚定地推行"全流程、一体化、国际化、多疗法"的核心战略，以客户需求为导向，深化全球化布 局，强化技术平台建设。2025年，公司预计营业收入同比增长13%—16%、归属于上市公司股东的扣除 非经常性损益后的净利润同比增长36%—41%、经调整的非《国际财务报告准则》下归属于上市公司股 东的净利润同比增长10%—15%。按业绩预告中位值测算，2025年第四季度，公司营业收入同比增长 14.79%、归属于上市公司股东的扣除非经常性损益后的净利润同比增长54.09%、经调整的非《国际财 务报告准则》下归属于上市公司股东的净利润同比增长16.36%。如上所述，报告期内归属于上市公司 股东的非经常性损益为人民币11,000万元至人民币13,000万元；上年同期主要由于处置 PROT ...

康龙化成公告称，康龙化成预计2025年归属于上市公司股东的净利润为16.14亿元-16.86亿元，比上年同 期下降6%-10%。报告期内，公司营业收入同比增长13%-16%，扣除非经常性损益后的净利润同比增长 36%-41%。 （文章来源：第一财经） ...

康龙化成公告，预计2025年度净利润为16.14亿元–16.86亿元，同比下降6%–10%。预计营业收入为 138.72亿元–142.4亿元，同比增长13%–16%。预计归属于上市公司股东的扣除非经常性损益后的净利润 为15.07亿元–15.62亿元，同比增长36%–41%。 ...

证券代码：300759 证券简称：康龙化成 公告编号：2026-003 以下为本公司的 2025 年年度业绩预告。本业绩预告所载之财务数据未经审 计，除经调整的非《国际财务报告准则》下归属于上市公司股东的净利润或另 有注释外，本业绩预告所载之财务数据根据中国企业会计准则编制。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 2、业绩预告情况：自愿性业绩预告 预计营业收入、归属于上市公司股东的扣除非经常性损益后的净利润以及经 调整的非《国际财务报告准则》下归属于上市公司股东的净利润同向上升，预计 归属于上市公司股东的净利润同向下降。 | 项 目 | 本报告期 | | 上年同期 | | --- | --- | --- | --- | | 营业收入 | 营收：1,387,162.56 | 万元–1,423,989.89 万元 | 营收：1,227,577.49 万元 | | | 比上年同期增长：13%–16% | | | | 归属于上市公司股东 | 盈利：161,401.57 | 万元–168,574.98 万元 | 盈利：179,335.08 万元 | | ...